Fennec Pharmaceuticals Inc. is a clinical-stage biotechnology company developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. STS as a protectant against the hearing loss often caused by platinum-based anti-cancer agents in children.

Children undergoing chemotherapy are going through an extraordinarily challenging time and the loss of hearing only compounds the difficulty. Fennec Pharma hopes that Sodium Thiosulfate will allow these children to keep their hearing and prevent permanent disability.

Preclinical and clinical studies conducted by OHSU and others have indicated that STS can effectively reduce the incidence of hearing loss caused by platinum-based anticancer agents.

TypePublic
HQDurham, US
Founded1996
Size (employees)3 (est)
Websitefennecpharma.com
Fennec Pharma was founded in 1996 and is headquartered in Durham, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Fennec Pharma

Rostislav Raykov

Rostislav Raykov

CEO
Robert Andrade

Robert Andrade

CFO
Show more

Fennec Pharma Office Locations

Fennec Pharma has an office in Durham
Show all (1)
Report incorrect company information

Fennec Pharma Financials and Metrics

Fennec Pharma Revenue

USD

Net income (Q2, 2018)

(4.2m)

EBIT (Q2, 2018)

(4.5m)

Cash (30-Jun-2018)

25.6m
Annual
USDFY, 2016FY, 2017

Revenue

General and administrative expense

2.4m5.0m

R&D expense

472.0k1.9m

Operating expense total

2.9m7.0m
Quarterly
USDQ3, 2013Q1, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Revenue

General and administrative expense

275.0k505.0k531.0k409.0k495.0k250.0k407.0k568.0k452.0k546.0k1.1m1.7m1.1m3.0m

R&D expense

224.0k32.0k88.0k54.0k88.0k47.0k139.0k112.0k225.0k333.0k492.0k689.0k1.5m

Operating expense total

51.0k537.0k619.0k409.0k549.0k338.0k454.0k707.0k564.0k771.0k1.5m2.2m1.8m4.5m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

1.7m2.3m942.0k3.9m28.3m

Total Assets

1.8m2.4m1.0m4.0m28.4m

Accounts Payable

212.0k308.0k297.0k244.0k855.0k

Current Liabilities

3.2m1.8m471.0k402.0k1.6m
Quarterly
USDQ3, 2013Q1, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

538.0k1.3m593.0k1.9m1.9m1.4m545.0k5.1m4.5m3.3m10.2m9.7m26.7m25.6m

Total Assets

640.0k1.4m673.0k1.9m1.9m1.5m588.0k5.1m4.6m3.3m10.3m9.9m26.8m25.7m

Accounts Payable

315.0k154.0k364.0k384.0k401.0k252.0k225.0k345.0k235.0k224.0k296.0k492.0k1.0m709.0k

Current Liabilities

5.7m3.9m1.1m759.0k431.0k345.0k451.0k360.0k427.0k580.0k1.0m1.2m847.0k
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

1.8m(2.8m)(7.0m)

Accounts Payable

(11.0k)(54.0k)611.0k

Cash From Operating Activities

(2.2m)(1.7m)(1.9m)(2.1m)(3.6m)

Cash From Financing Activities

2.3m497.0k5.1m28.0m
Quarterly
USDQ3, 2013Q1, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

(1.8m)(3.2m)380.0k177.0k(420.0k)(502.0k)(806.0k)(1.6m)(2.4m)(1.6m)(4.2m)

Accounts Payable

384.0k401.0k252.0k(72.0k)345.0k(110.0k)224.0k71.0k196.0k178.0k(146.0k)

Cash From Operating Activities

(469.0k)(378.0k)(443.0k)(499.0k)(544.0k)(688.0k)(958.0k)(1.7m)(3.3m)

Cash From Financing Activities

53.0k21.0k102.0k7.7m414.0k186.0k677.0k
USDY, 2018

Financial Leverage

1 x
Show all financial metrics
Report incorrect company information

Fennec Pharma Blogs

FENNEC PHARMACEUTICALS ANNOUNCES SCIENTIFIC SYMPOSIUM ON OTOTOXICITY IN PEDIATRIC CANCER PATIENTS AT THE 50TH CONGRESS OF THE INTERNATIONAL SOCIETY OF PEDIATRIC ONCOLOGY (SIOP) 2018 MEETING

Research Triangle Park, NC, November 16, 2018 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients,…

SEPTEMBER 13 MEETING WILL EXPLORE CHEMO-INDUCED HEARING LOSS IN PEDIATRICS

WASHINGTON, DC — Young adult survivors of childhood cancer and parents of children with cancer are invited to participate via webcast in a workshop on Chemotherapy-Induced Hearing Loss in Pediatrics, taking place in the DC metro area on September 13, 2018. This half-day event follows the Food and Dr…

FENNEC PHARMACEUTICALS RECEIVES POSITIVE OPINION ON THE PEDIATRIC INVESTIGATION PLAN FROM EUROPEAN MEDICINES AGENCY FOR PEDMARKTM AND CONFIRMATION OF ELIGIBILITY FOR A PEDIATRIC USE MARKETING AUTHORIZATION

Research Triangle Park, NC, August 7, 2018 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the Pediatric Committee (PDCO) of the European Medicines Agency (EMA) has accepted the Company’s pediatric investigation plan (PIP) for PEDMARKTM…

Fennec Announces Publication of Pedmark(TM) Siopel 6 Clinical Data in the New England Journal of Medicine

SIOPEL 6 met primary endpoint (p=0.002) 48% reduction in the incidence of hearing loss No evidence of tumor protection RESEARCH TRIANGLE PARK, N.C., June 21, 2018 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company focused on the development of …

Fennec Pharmaceuticals Set to Join Russell 3000 Index

Research Triangle Park, NC, June 11, 2018 – Fennec Pharmaceuticals Inc. (NASDAQ: FENC, TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients, an…

Fennec Announces Results of Annual Meeting

Research Triangle Park, NC — (Marketwired) – June 7, 2018– Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 30, 2018 (the “Circular”) for the Annual General and Special Meeting of Shareholders we…

Fennec Pharma Company Life and Culture

Report incorrect company information

Fennec Pharma Frequently Asked Questions

  • When was Fennec Pharma founded?

    Fennec Pharma was founded in 1996.

  • Who are Fennec Pharma key executives?

    Fennec Pharma's key executives are Rostislav Raykov and Robert Andrade.

  • How many employees does Fennec Pharma have?

    Fennec Pharma has 3 employees.

  • Who are Fennec Pharma competitors?

    Competitors of Fennec Pharma include Urogen Pharma, LAM Therapeutics and Achieve Life Sciences.

  • Where are Fennec Pharma offices?

    Fennec Pharma has an office in Durham.

  • How many offices does Fennec Pharma have?

    Fennec Pharma has 1 office.